Genetic Variants Linked to Multiple Non-melanoma Skin Cancers: A Study of 19 SNPs in an Italian Population - Summary - MDSpire

Genetic Variants Linked to Multiple Non-melanoma Skin Cancers: A Study of 19 SNPs in an Italian Population

  • By

  • Irene Campana

  • Ylenia Aura Minafò

  • Giovanni Luca Scaglione

  • Giulia Giovanardi

  • Terenzio Cosio

  • Caterina Lanna

  • Fabio Artosi

  • Sara Lambiase

  • Carola Valente

  • Valeria Bartolocci

  • Martina Morelli

  • Cristina Albanesi

  • Enzo Palese

  • Marilena Minieri

  • Alfredo Giovannelli

  • Daniele Avitabile

  • Nidia Margot Salcedo

  • Simona Mastroeni

  • Cinzia Mazzanti

  • Damiano Abeni

  • Elena Campione

  • Luca Fania

  • Elena Dellambra

  • April 11, 2026

  • 0 min

Share

Objective:

To investigate the association of selected genetic variants with the risk of developing multiple non-melanoma skin cancers (NMSCs) in an Italian population, highlighting the significance of genetic factors in NMSC susceptibility.

Key Findings:
  • 19 genetic variants were significantly associated with NMSC multiplicity, with implications for future research and clinical practice.
Interpretation:

Integrating genetic and environmental factors can enhance personalized prevention strategies for individuals at higher risk of developing multiple NMSCs, considering their interactions.

Limitations:
  • The study was limited to an Italian population, which may affect generalizability to other demographics.
Conclusion:

Identifying SNPs associated with NMSC multiplicity may improve risk stratification and support personalized prevention strategies, impacting public health initiatives.

Original Source(s)

Genetic Variants Linked to Multiple Non-melanoma Skin Cancers: A Study of 19 SNPs in an Italian Population

  • by Irene Campana, Ylenia Aura Minafò, Giovanni Luca Scaglione, Giulia Giovanardi, Terenzio Cosio, Caterina Lanna, Fabio Artosi, Sara Lambiase, Carola Valente, Valeria Bartolocci, Martina Morelli, Cristina Albanesi, Enzo Palese, Marilena Minieri, Alfredo Giovannelli, Daniele Avitabile, Nidia Margot Salcedo, Simona Mastroeni, Cinzia Mazzanti, Damiano Abeni, Elena Campione, Luca Fania, Elena Dellambra

  • April 11, 2026

Related Content

Comprehensive Evaluation of Tirbanibulin for Treating Actinic Keratosis: A European Multi-Criteria Decision Analysis Study

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.